SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that treatment with PEGPH20 significantly delayed tumor growth in breast and prostate cancer models. Moreover, in a brain metastasis model, PEGPH20 combined with chemotherapy showed increased efficacy and PEGPH20 combined with radiation prolonged survival. PEGPH20 targets and degrades the hyaluronan (HA) coating that surrounds certain solid tumor cells. Halozyme presented its findings at the American Association for Cancer Research (AACR) meeting in Denver.
